Диссертация (Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения), страница 34

/ Dhein S. [etal.] // Naunyn Schmiedebergs Arch Pharmacol. – 2010- Vol 381(3) – P.221–234133. DinovB.Impactofmetabolicsyndromeonleftatrialelectroanatomical remodeling and outcomes after radiofrequency ablation ofnonvalvular atrial fibrillation. / Dinov B. [et al.] // Circ Arrhythm Electrophysiol.2014 - Vol 7(3)- P.483-9.134. Disertori M. Valsartan for prevention of recurrent atrial fibrillation./Disertori M.

[et al.] // N Engl J Med – 2009 – Vol 360- P.1606 –17.135. Disertori M. Clinical characteristics of patients with asymptomaticrecurrences of atrial fibrillation in the Gruppo Italiano per lo Studio dellaSopravvivenza nell’Infarto Miocardico- Atrial Fibrillation (GISSI-AF) trial. /Disertori M. [et al.] // Am Heart J – 2011- Vol 162 – P. 382-389.136. Dixen U. Raised plasma aldosterone and natriuretic peptides in atrialfibrillation./ Dixen U.

[et al.] // Cardiology. – 2007- Vol 108(1)-P.35-9.137. Dobrev D. New antiarrhythmic drugs for treatment of atrialfibrillation./ Dobrev D, Nattel S. // Lancet. – 2010- 375(9721)- P.1212–1223.138. Dobrev D. The ryanodine receptor channel as a molecular motif inatrial fibrillation: pathophysiological and therapeutic implications./ Dobrev D. [etal.] // Cardiovasc Res.- 2011- 89(4)- P.734–743.139. Ducharme A. Prevention of atrial fibrillation in patients withsymptomatic chronic heart failure by candesartan in the Candesartan in HeartFailure: Assessment of Reduction in Mortality and Morbidity (CHARM)program. / Ducharme A.

[et al.] // Am Heart J 2006 –Vol 152- P.86 –92.140. El-Armouche A. Molecular determinants of altered Ca2+ handling inhuman chronic atrial fibrillation. / El-Armouche A. [et al.] // Circulation- 2006Vol 114(7)- P. 670–680.141. Ellinor PT. Common variants in KCNN3 are associated with loneatrial fibrillation. / Ellinor PT. [et al.] //Nat Genet. – 2010- Vol 42(3)- P.240–244.237142. ESH-ESC Guidelines Committee.

2013 ESH-ESC guidelines for themanagement of arterial hypertension.// J Hypertension – 2013-Vol 31-P.12811357.143. Fang WT. The role of statin therapy in the prevention of atrialfibrillation: a meta-analysis of randomized controlled trials./ Fang WT. [et al.] //Br J Clin Pharmacol- 2012 –Vol 74- P.744–56.144.

Fauchier L. Antiarrhythmic effect of statin therapy and atrialfibrillation a meta-analysis of randomized controlled trials./ Fauchier L. [et al.] //J Am Coll Cardiol – 2008- Vol 51- P.828–35.145. Flaker GC Asymptomatic atrial fibrillation: demographic featuresand prognostic information from the Atrial Fibrillation Follow-up Investigation ofRhythm Management (AFFIRM) study./ Flaker GC [et al.] // Am Heart J.

- 2005Vol 149- P.657–63.146. Fogari R. Effect of valsartan and ramipril on atrial fibrillationrecurrence and P-wave dispersion in hypertensive patients with recurrentsymptomatic lone atrial fibrillation. / Fogari R. [et al.]//Am J Hypertens 2008Vol 21- P.1034 –9.147.

Fogari R. Losartan and prevention of atrial fibrillation recurrence inhypertensive patients. / Fogari R. [et al.] //J Cardiovasc Pharmacol – 2006- Vol47- P.46 –50.148. Fogari R. Comparative evaluation of effect of valsartan/amlodipineand atenolol/amlodipine combinations on atrial fibrillation recurrence inhypertensive patients with type 2 diabetes mellitus. / Fogari R. [et al.]//JCardiovasc Pharmacol – 2008- Vol 51- P.217–22.149. Friberg L. Evaluation of risk stratification schemes for ischaemicstroke and bleeding in 182 678 patients ith atrial fibrillation: the Swedish AtrialFibrillation cohort study/ Friberg L. [et al.] // EurHeart – 2012- Vol 33- P. 150010.238150. Gage B.F.

Validation of clinical classification schemes for predictingstroke: results from the National Registry of Atrial Fibrillation./ Gage B.F. [et al.]//JAMA – 2001 –Vol 285- P.2864–2870151. Galvão Braga C. New-onset atrial fibrillation during acute coronarysyndromes: predictors and prognosis./ Galvão Braga C [et al.] // Rev Port Cardiol.2014 – Vol 33(5)- P.281-7.152. Gallagher, M.M. Classification of atrial fibrillation. / GallagherM.M. [et al.] // Am J Cardiol. – 1998- Vol 82- P.18–28.153. Gami AS. Obstructive sleep apnea, obesity, and the risk of incidentatrial fibrillation / Gami AS. [et al.] // J Am Coll Cardiol - 2007 – Vol 49(5)P.565-71.154. Gassanov N. Angiotensin II–induced changes of calcium sparks andionic currents in human atrial myocytes: potential role for early remodeling inatrial fibrillation.

/ Gassanov N. [et al.]//Cell Calcium – 2006 – Vol 39(2)-P.175–186.155. George J. High-dose allopurinol improves endothelial function byprofoundly reducing vascular oxidative stress and not by lowering uric acid./George J. [et al.] // Circulation – 2006- Vol 114- P.2508–16.156. Givertz MM. Xanthine oxidase inhibition for hyperuricemic heartfailure patients: design and rationale of the EXACT-HF study. / Givertz MM. [etal.] // Circ Heart Fail – 2013- Vol 6- P.862–8.157. Go A.S. Prevalence of diagnosed atrial fibrillation in adults: nationalimplications for rhythm management and stroke prevention: the AnTicoagulationand Risk Factors in Atrial Fibrillation (ATRIA) Study. / Go A.S. [et al.]//JAMA – 2001 – Vol 285- P.

2370–2375.158. Go AS. ATRIA Study Investigators. Impact of proteinuria andglomerular filtration rate on risk of thromboembolism in atrial fibrillation: theanticoagulation and risk factors in atrial fibrillation (ATRIA) study./ Go AS. [etal.] //Circulation – 2009-Vol 119- P.1363-9.239159. Go AS. American Heart Association Statistics Committee and StrokeStatistics Subcommittee. Heart disease and stroke statistics 2014 update: a reportfrom the American Heart Association./ Go AS. [et al.] // Circulation – 2014- Vol21;129(3)- P.28-292.160. Goette, A.

EHRA/HRS/APHRS/SOLAECE expert consensus onatrial cardiomyopathies: definition, characterization, and clinical implication. /Goette, A. [et al.] // Heart Rhythm. – 2017- Vol 14- P.3–40.161. Grecu M. Does treatment with ACE inhibitors prevent the long termrecurrences of lone atrial fibrillation after cardioversion? / Grecu M.

[et al.]//Rom J Intern Med – 2007- Vol 45- P.29 –33.162. Greiser M. Distinct contractile and molecular differences betweentwo goat models of atrial dysfunction: AV block-induced atrial dilatation andatrial fibrillation / Greiser M. [et al.] // J Mol Cell Cardiol.- 2009- Vol 46(3P.385–394.163. Gronefeld GC. Heart failure complicated by atrial fibrillation:mechanistic, prognostic, and therapeutic implications. /Gronefeld GC, HohnloserSH. // J. Cardiovasc. Pharmacol. Ther.- 2003- Vol 8(2)- P.107-113.164.

Guidelines for management of atrial fibrillation. The task force forthe management of Atrial Fibrillation of European Society of Cardiology (ESC)// Eur. Heart J. – 2013- Vol 31 (19)- P. 2369-439.165. Haim M. Prospective national study of the prevalence, incidence,management and outcome of a large contemporary cohort of patients withincident non-valvular atrial fibrillation/ Haim M.

[et al.] // Journal of theAmerican Heart Association- 2015-Vol 4(1)- P.1486–95.166. Hamaguchi S. Effects of atrial fibrillation on long-term outcomes inpatients hospitalized for heart failure in Japan: a report from the Japanese CardiacRegistry of Heart Failure in Cardiology (JCARE-CARD)/ Hamaguchi S. [et al.]// Circ J – 2009- Vol 73- P.2084–90.240167. Hanrahan J.P. Arrhythmias in patients with chronic obstructivepulmonary disease (COPD): occurrence frequency and the effect of treatmentwith the inhaled long-acting beta2-agonists arformoterol and salmeterol./Hanrahan J.P. [et al.] // Medicine Baltimore – 2008- Vol 87(6)-P.319-28.168.

Hansson L. Randomised trial of old and new antihypertensive drugsin elderly patients: cardiovascular mortality and morbidity the Swedish Trial inOld Patients With Hypertension-2 study. / Hansson L. [et al.] // Lancet 1999- Vol354-P.1751– 6.169. Hansson L. Effect of angiotensinconverting-enzyme inhibitioncompared with conventional therapy on cardiovascular morbidity and mortality inhypertension: the Captopril Prevention Project (CAPPP) randomised trial. /Hansson L. [et al.] // Lancet – 1999- Vol 353-P. 611–6.170. Hart R.G. Meta-analysis: antithrombotic therapy to prevent stroke inpatients who have nonvalvular atrial fibrillation. / Hart R.G.